Evidence map›Paper›PMID 41042191›Full record

ArticleJACC. CardioOncology2025

Inhibition, But Not Depletion, of Erk Signaling Ameliorates Anthracycline-Induced Cardiotoxicity in Zebrafish.

Maryam Moossavi, Ping Zhu, Yonghe Ding, David Mondaca-Ruff, Feixiang Yan, Xueling Ma, Xiaolei Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. CardioOncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maryam MoossaviDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Ping ZhuDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Yonghe DingDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
David Mondaca-RuffDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Feixiang YanDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Xueling MaDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA; Beijing University of Chinese Medicine, Beijing, China.
Xiaolei XuDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: xu.xiaolei@mayo.edu.

Funding

Genetic Studies of Sarcomere-based Cardiac Diseases (Diversity Supplement)R01HL081753 · NHLBI · MAYO CLINIC ROCHESTER · PI XU, XIAOLEI · 2005 to 2025
$7.8M
Discovering aging-associated genetic modifiers and therapies for anthracycline-induced cardiotoxicityR01HL176555 · NHLBI · MAYO CLINIC ROCHESTER · PI Nadine Norton, Xiaolei Xu · 2025 to 2026
$1.3M
NHLBI NIH HHS R01 HL081753NHLBI NIH HHS R01 HL176555
6 · The paper itself

Abstract

backgroundAnthracycline-induced cardiotoxicity (AIC) is a unique type of cardiomyopathy that limits the clinical use of anthracyclines in cancer therapy. Although several cardiomyopathy-related pathways have been identified, including extracellular signal-regulated kinase (ERK) signaling, pathway-specific interventions for AIC remain unclear.

objectivesThe aim of this study was to investigate the role of Erk signaling in AIC using zebrafish genetics.

methodsA zebrafish model of AIC was used to screen genes in known cardiomyopathy pathways, including Erk signaling. Heterozygous and homozygous mutants were evaluated for their modifying effects on AIC. In parallel, pharmacologic studies with ERK inhibitors were conducted to assess dose-dependent therapeutic effects of Erk inhibition.

resultsmek1

conclusionsAberrant Erk activation contributes to AIC, and controlled Erk inhibition may offer therapeutic benefit, potentially via antiaging mechanisms. However, optimization is essential, as excessive inhibition can be cardiotoxic.

Indexed as

aginganthracyclinescardiotoxicityErksenescencezebrafish

Identifiers

PMID41042191
PMCPMC12805405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.